Hookipa Pharma Logo Square.png
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024 17:01 ET | HOOKIPA Pharma Inc.
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
April 25, 2024 07:01 ET | HOOKIPA Pharma Inc.
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback ...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024 07:01 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
April 10, 2024 07:01 ET | HOOKIPA Pharma Inc.
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 22, 2024 07:01 ET | HOOKIPA Pharma Inc.
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
January 29, 2024 08:01 ET | HOOKIPA Pharma Inc.
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
January 16, 2024 07:01 ET | HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
December 21, 2023 07:01 ET | HOOKIPA Pharma Inc.
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
November 20, 2023 07:01 ET | HOOKIPA Pharma Inc.
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for human immunodeficiency virus (HIV)Phase 1...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023 07:01 ET | HOOKIPA Pharma Inc.
Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong...